Repligen to Acquire Metenova AB

Strategic acquisition of Metenova expands Fluid Management portfolio Differentiated high performance mixing technology • Metenova is an innovator and a market leader in mixing technology • High efficiency mixing, improved yield and ● compelling ROI for customers Vertical integration with NMS vessels and FlexBiosys bags ● NMS provides plastic fabricated solutions to Metenova Future integration of FlexBiosys single-use bags with Metenova and drive train technology • Allows full control of supply chain R REPLIGEN ● Expands Fluid Management capabilities Adds stainless steel (repeat-use) and single-use mixing technology to portfolio ● • Mixing solutions for media, buffer preparation and shear sensitive proteins ● Leverage stainless steel success in promoting single-use solutions Metenova is a leader in the stainless steel (repeat-use) market with a broad portfolio of mixing technology Used by >80% of top 20 biopharma companies (based on reported 2022 revenue) *Source: Arthur D. Little analysis (Market size as of 2022) ● ● ● ● ● Expands our total addressable market (TAM) Allows RGEN to enter ~$1B mixing market* Supports manufacturing across modalities: - Small molecule, mAbs, rProteins - Vaccines, Cell & Gene Therapy Primary installed base: Biopharma, CDMO Meets Repligen's M&A criteria Differentiated technology - adds impellers (mixer heads) and drive trains to portfolio Strong revenue growth: ~15% in 2023e, 20%-25% in 2025 and forward Expected to be accretive to adj. margins in 2024 and to adj. EPS in 2025 metem nova 3

View entire presentation